Karyopharm Therapeutics Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $146.1M | $145.2M | $146.0M | $157.1M | $209.8M | $108.1M | $40.9M | $30.3M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $125.6M | $143.2M | $138.8M | $148.7M | $160.8M | $150.8M | $122.3M | $161.4M |
| SG&A Expense | $105.2M | $115.4M | $131.9M | $145.4M | $143.8M | $126.4M | $105.4M | $48.8M |
| Operating Income | $-90.7M | $-119.4M | $-129.5M | $-142.2M | $-98.3M | $-171.9M | $-189.3M | $-179.9M |
| Operating Margin | -62.1% | -82.2% | -88.7% | -90.5% | -46.8% | -159.0% | -462.9% | -593.0% |
| Interest Expense | — | — | $23.8M | $25.0M | $26.0M | $27.1M | $15.6M | $2.5M |
| Pretax Income | $-196.0M | $-76.4M | $-142.8M | $-164.9M | $-123.8M | $-196.0M | $-199.6M | $-178.4M |
| Income Tax Expense | $43.0K | $57.0K | $323.0K | $369.0K | $268.0K | $309.0K | $40.0K | $26.0K |
| Net Income | $-196.0M | $-76.4M | $-143.1M | $-165.3M | $-124.1M | $-196.3M | $-199.6M | $-178.4M |
| Net Margin | -134.2% | -52.6% | -98.0% | -105.2% | -59.1% | -181.6% | -488.1% | -588.1% |
| EPS (Basic) | $-17.93 | $-9.41 | $-18.79 | $-2.02 | $-1.65 | $-2.72 | $-3.22 | $-3.14 |
| EPS (Diluted) | $-17.93 | $-14.00 | $-18.79 | $-2.02 | $-1.65 | $-2.72 | $-3.22 | $-3.14 |
| Shares Outstanding (Basic) | 10.9K | 8.1K | 114.2M | 81.9M | 75.2M | 72.0M | 65.4M | 60.8M |
| Shares Outstanding (Diluted) | 10.9K | 8.5K | 114.2M | 81.9M | 75.2M | 72.0M | 65.4M | 60.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |